c5b

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Acetyl-Histone H3 (Lys9) (C5B11) Rabbit mAb #9649R is a useful organic compound for research related to life sciences and the catalog number is T64611.

Anti-UNC5B Antibody (YW88) is a monoclonal antibody targeting UNC5B. It can inhibit the binding of Netrin-1 to Unc5B and is applicable in angiogenesis research.

Tert-Butyl5-bromo-1H-indole-1-carboxylate (N-Boc-5-bromoindole) is an indole derivative with therapeutic potential for pain, inflammation, and other conditions.

(S,R,S)-AHPC-Me-amide-C-O-C5-Br is a compound that includes a VHL ligand for recruiting E3 ubiquitin ligase, along with a linker. This compound is utilized in the synthesis of various PROTAC molecules, such as [ERD-308].

2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br is an E3 ligase ligand-linker conjugate utilized in the synthesis of PROTAC.

Freselestat (ONO-6818) is a potent neutrophil elastase inhibitor that significantly reduces the production of interleukin 8 and C5B-9, thereby decreasing inflammatory mediators during simulated cardiopulmonary bypass.

ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched for its potential application in the treatment of age-related macular degeneration (AMD).

Crovalimab (SKY59; RO7112689) is an Fc-engineered and pH-dependent humanised monoclonal antibody that binds to complement C5 and blocks its cleavage into C5a and C5b, thereby inhibiting MAC formation and intravascular haemolysis. It can rebind to the FcRn receptor under acidic pH conditions and return to the bloodstream, making it suitable for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Anti-CD59 Antibody is a humanized monoclonal antibody targeting CD59 (Protectin/MAC-IP). CD59 is a GPI-anchored complement regulatory protein widely expressed on cell surfaces. It protects host cells from complement-mediated lysis by binding to complement components C8 and C9, thereby preventing the final assembly of the Membrane Attack Complex (MAC/C5b-9). CD59 is often overexpressed in various solid tumors and hematologic malignancies, enabling tumor cells to evade immune surveillance. This antibody specifically binds to CD59, blocking its inhibition of MAC assembly to restore tumor cell sensitivity to complement and induce potent Complement-Dependent Cytotoxicity (CDC). It serves as a critical tool for investigating tumor immune evasion and developing enhanced complement-based immunotherapies.